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Abstract
© Ramirez et al. 2015. Background: Overexpression or mutation of the epidermal growth factor
receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently
display  resistance  to  mechanistically-distinct  EGFR-directed  therapeutic  agents,  making  it
valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting
therapeutics  include  antibodies  targeting  the  extracellular  domains,  and  small  molecules
inhibiting  the  intracellular  kinase  domain.  Recent  studies  have  identified  a  novel  prone
extracellular tetrameric EGFR configuration, which we identify as a potential target for drug
discovery. Methods: Our focus is on the prone EGFR tetramer, which contains a novel protein-
protein  interface  involving  extracellular  domain  III.  This  EGFR  tetramer  is  computationally
targeted  for  stabilization  by  small  molecule  ligand  binding.  This  study  performed  virtual
screening of  a Life Chemicals,  Inc.  small  molecule library of  345,232 drug-like compounds
against  a  molecular  dynamics simulation of  protein-protein interfaces distinct  to  the novel
tetramer.  One  hundred  nine  chemically  diverse  candidate  molecules  were  selected  and
evaluated  using  a  cell-based  high-content  imaging  screen  that  directly  assessed  induced
internalization  of  the  EGFR effector  protein  Grb2.  Positive  hits  were  further  evaluated  for
influence on phosphorylation of EGFR and its effector ERK1/2. Results: Fourteen hit compounds
affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited
effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit
compound poses generally include Arg270 or neighboring residues, which are also involved in
binding the effective therapeutic cetuximab, guiding further chemical optimization. Conclusions:
These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target.
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